Clinical Trial Update: Rituximab in Systemic Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

Rituximab is being evaluated for systemic sclerosis in Phase 2 and Phase 3 trials, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Systemic Sclerosis | Phase 2, Phase 3 | Status: COMPLETED